• Draganfly (DPRO) unveils Vital Intelligence Smart Vital Kiosk at the CES 2022 in Las Vegas
  • Smart Vital Kiosk can screen temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation
  • Smart Vital Kiosk is part of Draganfly’s Vital Intelligence health and safety solution which is able to screen, detect, access and provide continuous action against the potential threat of infectious diseases, such as COVID-19
  • Draganfly (DPRO) is down 4.07 per cent at C$2.12 per share at 2:08 PM EST

Draganfly (DPRO) has unveiled the Vital Intelligence Smart Vital Kiosk at the CES 2022 in Las Vegas.

The Smart Vital Kiosk can screen body temperature, blood pressure, heart rate, respiratory rate, and oxygen saturation. The system does not register any personal data of the individual being screened.

The Smart Vital Kiosk is powered by Draganfly’s Vital Intelligence platform.

This Smart Vital system is part of Draganfly’s Vital Intelligence health and safety solution, which is able to screen, detect, access and provide continuous action against the potential threat of infectious diseases, such as COVID-19.

The Smart Vital Kiosk’s LCD screen is accessible, according to the Americans with Disabilities Act and its infrared thermal camera adheres to Food and Drug Administration’s guidelines.

Paul Mullen, Vice President of Vital Intelligence at Draganfly remarked on the Smart Vital Kiosk.

“We are committed to providing seamless and non-invasive solutions that allow organizations to host safe events and gatherings. Utilizing proprietary software built by Draganfly, the new Smart Vital Kiosk enables multi-dimensional screening of core vitals to provide real-time health insights in seconds.”

Draganfly is a corporation focusing on drone solutions, software and AI systems in regards to public safety, agriculture, and security.

Draganfly (DPRO) is down 4.07 per cent at C$2.12 per share at 2:08 PM EST.

More From The Market Online

Buzz on the Bullboards: Who benefits from the latest stock market rally?

Investors are eagerly anticipating top corporate earnings this week, seeking further insights into market trends and potential opportunities.

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.